Top

Pediatric Nephrology

Published in:

Open Access 01-09-2013 | Original Article

Urine NGAL and KIM-1 in children and adolescents with hyperuricemia

Authors: Justyna Tomczak, Anna Wasilewska, Robert Milewski

Published in: Pediatric Nephrology | Issue 9/2013

Abstract

Background

The aim of this study was to test the hypothesis that urine levels of neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) are enhanced in pediatric patients with hyperuricemia.

Methods

The study included 88 children and adolescents (60 males, 28 females) with a median age of 16 (range 11–18.5) years who had been referred to our department to rule out or confirm hypertension. The subjects were divided into two groups: the hyperuricemic (HU) group comprising 59 subjects with hyperuricemia (defined as serum uric acid >4.8 and >5.5 mg/dl in girls and boys, respectively) and the reference group comprising 29 patients with normouricemia. Urine NGAL and KIM-1 levels were evaluated using a commercially available kit.

Results

Concentrations of the examined biomarkers [urine NGAL, NGAL/creatinine (cr.) ratio, urine KIM-1, KIM-1/cr. ratio] were increased in the HU group compared with the reference group (p < 0.01). There were positive correlations between the serum uric acid and urine NGAL/cr. ratio (R = 0.67, p < 0.001) and the urine KIM-1/cr. ratio (R = 0.36, p < 0.001). In the multiple regression models, serum uric acid, systolic blood pressure and cholesterol accounted for more than 49 % of the variation in the NGAL/cr. ratio (R = 0.702, p < 0.001). In the second model, serum uric acid, gender, age and systolic blood pressure accounted for more than 36 % of the variation in the KIM-1/cr. ratio (R = 0.604, p < 0.001).

Conclusion

We demonstrated that male, obese, hypertensive adolescents with hyperuricemia have higher urine NGAL and KIM-1 levels relative to a reference group with normouricemia.

Feig DI (2009) Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 18:526–530PubMedCrossRef

Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ (2002) Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282:F991–F997PubMed

Sánchez-Lozada LG, Tapia E, Santamaría J, Avila-Casado C, Soto V, Nepomuceno T, Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J (2005) Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67:237–247PubMedCrossRef

Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, Johnson RJ (2003) Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 23:2–7PubMedCrossRef

Ryu ES, Kim MJ, Shin HS, Jang YH, Choi HS, Jo I, Johnson RJ, Kang DH (2013) Uric acid- induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol 304:F471–F480PubMedCrossRef

Ji B, Zhang S, Gong L, Wang Z, Ren W, Li Q, Li R (2013) The risk factors of mild decline in estimated glomerular filtration rate in a community-based polulation. Clin Biochem. doi: 10.1016/j.clinbiochem.2013.01.011

Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359:1811–1821PubMedCrossRef

Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, Covic A (2007) Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 39:1227–1233PubMedCrossRef

Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47:51–59PubMedCrossRef

10.

Bagshaw SM, Bellomo R (2007) Early diagnosis of acute kidney injury. Curr Opin Crit Care 13:638–644PubMedCrossRef

11.

Venge P, Carlson M, Fredens K, Garcia R (1999) The 40 kD-protein. A new protein isolated from the secondary granules of human neutrophils: Joint International Conference on Leukocyte Biology. J Leukocyte Biol 1:28

12.

Allen RA, Erickson RW, Jesaitis AJ (1989) Identification of a human neutrophil protein of Mr 24 000 that binds N-formyl peptides: co-sedimentation with specific granules. Biochim Biophys Acta 991:123–133PubMedCrossRef

13.

Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, Sanicola M (1998) Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 273:4135–4142PubMedCrossRef

14.

Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV (2002) Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 62:237–244PubMedCrossRef

15.

Cherian S, Crompton CH (2005) Partial hypoxanthine-guanine phosphoribosyltransferase deficiency presenting as acute renal failure. Pediatr Nephrol 20:1811–1813PubMedCrossRef

16.

Lock EA (2010) Sensitive and early markers of renal injury: where are we and what is the way forward? Toxicol Sci 116:1–4PubMedCrossRef

17.

Feig DI, Johnson RJ (2003) Hyperuricemia in childhood primary hypertension. Hypertension 42:247–252PubMedCrossRef

18.

Xu PC, Zhang JJ, Chen M, Lv JC, Liu G, Zou WZ, Zhang H, Zhao MH (2011) Urinary kidney injury molecule-1 in patients with IgA nephropathy is closely associated with disease severity. Nephrol Dial Transplant 26:3229–3236PubMedCrossRef

19.

Yang YH, He XJ, Chen SR, Wang L, Li EM, Xu LY (2009) Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. Endocrine 36:45–51PubMedCrossRef

20.

Bolignano D, Coppolino G, Campo S, Aloisi C, Nicocia G, Frisina N, Buemi M (2007) Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am J Nephrol 27:373–378PubMed

21.

Miatello R, Vázquez M, Renna N, Cruzado M, Zumino AP, Risler N (2005) Chronic administration of resveratrol prevents biochemical cardiovascula changes in fructose-fed rats. Am J Hypertens 18:864–870PubMedCrossRef

22.

Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ (2006) A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290:F625–F631PubMedCrossRef

23.

Gersch MS, Mu W, Cirillo P, Reungjui S, Zhang L, Roncal C, Austin YY, Johnson RJ, Nakagawa T (2007) Fructose, but not dextrose, accelerates the progression of chronic kidney disease. Am J Physiol Renal Physiol 293:F1256–F1261PubMedCrossRef

24.

Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888–2897PubMedCrossRef

25.

Hu QH, Wang C, Li JM, Zhang DM, Kong LD (2009) Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement. Am J Physiol Renal Physiol 297:F1080–F1091PubMedCrossRef

26.

Le MT, Shafiu M, Mu W, Johnson RJ (2008) SLC2A9-A fructose transporter identified as a novel uric acid transporter. Nephrol Dial Transplant 23:2746–2749PubMedCrossRef

27.

Matsuzaki T, Watanabe H, Yoshitome K, Morisaki T, Hamada A, Nonoguchi H, Kohda Y, Tomita K, Inui K, Saito H (2008) Altered pharmacokinetics of cationic drugs caused by down-regulation of renal rat organic cation transporter 2 (Slc22a2) and rat multidrug and toxin extrusion 1 (Slc47a1) in ischemia/reperfusion-induced acute kidney injury. Drug Metab Dispos 36:649–654PubMedCrossRef

28.

Habu Y, Yano I, Okuda M, Fukatsu A, Inui K (2005) Restored expression and activity of organic ion transporters rOAT1, rOAT3 and rOCT2 after hyperuricemia in the rat kidney. Biochem Pharmacol 69:993–999PubMedCrossRef

29.

Grover B, Buckley D, Buckley AR, Cacini W (2004) Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes. J Pharmacol Exp Ther 308:949–956PubMedCrossRef

30.

Rizwan AN, Burckhardt G (2007) Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 24:450–470PubMedCrossRef

31.

Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26:269–275PubMedCrossRef

32.

Yu MA, Sánchez-Lozada LG, Johnson RJ, Kang DH (2010) Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 28:1234–1242PubMed

33.

Han HJ, Lim MJ, Lee YJ, Lee JH, Yang IS, Taub M (2007) Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-kappaB. Am J Physiol Renal Physiol 292:F373–F381PubMedCrossRef

34.

Quan H, Peng X, Liu S, Bo F, Yang L, Huang Z, Li H, Chen X, Di W (2011) Differentially expressed protein profile of renal tubule cell stimulated by elevated uric acid using SILAC coupled to LC-MS. Cell Physiol Biochem 27:91–98PubMed

35.

Ding H, He Y, Li K, Yang J, Li X, Lu R, Gao W (2007) Urinary neutrophil gelatinase- associated lipocalin (NGAL)) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol 123:227–234PubMedCrossRef

36.

Brunner HI, Mueller M, Rutherford C, Passo MH, Witte D, Grom A, Mishra J, Devarajan P (2006) Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum 54:2577–2584PubMedCrossRef

37.

Wasilewska A, Taranta-Janusz K, Dębek W, Zoch-Zwierz W, Kuroczycka-Saniutycz E (2011) KIM-1 and NGAL: new markers of obstructive nephropathy. Pediatr Nephrol 26:579–586PubMedCrossRef

38.

Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV (2004) Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 286:F552–F563PubMedCrossRef

39.

Kuehn EW, Park KM, Somlo S, Bonventre JV (2002) Kidney injury molecule-1 expression in murine polycystic kidney disease. Am J Physiol Renal Physiol 283:F1326–F1336PubMed

40.

Han WK, Alinani A, Wu CL, Michaelson D, Loda M, McGovern FJ, Thadhani R, Bonventre JV (2005) Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol 16:1126–1134PubMedCrossRef

41.

Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV (2006) Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 290:F517–F529PubMedCrossRef

42.

Nepal M, Bock GH, Sehic AM, Schultz MF, Zhang PL (2008) Kidney injury molecule-1 expression identifies proximal tubular injury in urate nephropathy. Ann Clin Lab Sci 38:210–214PubMed

43.

Eirin A, Gloviczki ML, Tang H, Rule AD, Woollard JR, Lerman A, Textor SC, Lerman LO (2012) Chronic renovascular hypertension is associated with elevated levels of neutrophil gelatinase-associated lipocalin. Nephrol Dial Transplant 27:4153–4161PubMedCrossRef

44.

Blumczynski A, Sołtysiak J, Lipkowska K, Silska M, Poprawska A, Musielak A, Zaniew M, Zachwieja J (2012) Hypertensive nephropathy in children—do we diagnose early enough? Blood Press 21:233–239PubMedCrossRef

45.

Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, Thorén P, Hansson GK (2006) Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 26:136–142PubMedCrossRef

Title: Urine NGAL and KIM-1 in children and adolescents with hyperuricemia
Authors: Justyna Tomczak
Anna Wasilewska
Robert Milewski
Publication date: 01-09-2013
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 9/2013
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-013-2491-y

At a glance: The STEP trials

Springer Medicine

Urine NGAL and KIM-1 in children and adolescents with hyperuricemia

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2013

Angiogenesis and autosomal dominant polycystic kidney disease

Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1

A single-center cohort of Canadian children with VUR reveals renal phenotypes important for genetic studies

Membrane trafficking in podocyte health and disease

TLR-4 polymorphisms and leukocyte TLR-4 expression in febrile UTI and renal scarring

Aortic bypass and bilateral renal autotransplantation for mid-aortic syndrome